Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II carboplatin + paclitaxel + bevacizumab followed by bevacizumab + erlotinib beyond progression in advanced non-small cell lung cancer
2007-005523-15Phase 2Terminated
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, erlotinib, carboplatin and paclitaxel in non-small cell lung cancer (NSCLC), sponsored by Radboud University Medical Center. Primary endpoints: Disease control rate at 18 weeks during bevacizumab plus erlotinib treatment and Maximum achieved disease control rate. Started Jun 2008; status: terminated.
02
Drugs
bevacizumaberlotinibcarboplatinpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-005523-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005523-15.